Moutzouri Stella, Pivodic Aldina, Haidich Anna-Bettina, Seliniotaki Aikaterini K, Lithoxopoulou Maria, Tsakalidis Christos, Hellström Ann, Ziakas Nikolaos, Mataftsi Asimina
2nd Department of Ophthalmology, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Department of Clinical Neuroscience, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Acta Ophthalmol. 2025 May;103(3):272-280. doi: 10.1111/aos.16788. Epub 2024 Nov 6.
To assess the predictive performance of DIGIROP-v1.0 models in identifying treatment-requiring ROP among infants undergoing ROP screening at a tertiary neonatal intensive care unit in Greece.
Retrospective cohort analysis of 640 consecutive screened preterm infants with gestational age (GA) 24 to 30 weeks and known ROP outcome in the 2nd Neonatology Department of Aristotle University of Thessaloniki (2009-2021). The primary outcome was the development of type 1 ROP according to the Early Treatment of ROP criteria or treatment based on the ophthalmologist's judgement. Sensitivity, specificity, area under the curve (AUC) with corresponding 95% confidence intervals (CI) and calibration plots for the DIGIROP-v1.0 models were displayed.
The DIGIROP-Birth-v1.0 model correctly identified 35/43 treated infants (sensitivity 81.4% [95% CI, 66.6%-91.6%], specificity 61.5% [95% CI, 57.4%-65.4%], AUC 0.82 [95% CI, 0.75-0.90]). During the postnatal weeks 6-14 the sensitivity of the DIGIROP-Screen-v1.0 model ranged from 82.6% to 100%. Eleven infants, all with severe comorbidities, that is, congenital malformation(s), syndrome(s), hydrocephalus or history of intestinal surgery, that were treated, were missed by the model, but met criteria for screening according to DIGIROP-v1.0 models' recommendations, and to our unit's routine standards.
The DIGIROP-v1.0 models resulted in lower sensitivity and higher specificity in this Greek cohort compared with the Swedish development group. Despite higher GA and BW, infants in our cohort had higher incidence of treated ROP than in Sweden, resulting in an under-estimation of their risk for treatment-requiring ROP. Further validation of the DIGIROP-v2.0 models and potential adjusting are recommended to maximize generalizability in populations with different characteristics.
评估DIGIROP-v1.0模型在希腊一家三级新生儿重症监护病房接受视网膜病变(ROP)筛查的婴儿中识别需要治疗的ROP的预测性能。
对塞萨洛尼基亚里士多德大学第二新生儿科连续筛查的640例胎龄(GA)为24至30周且已知ROP结局的早产婴儿进行回顾性队列分析(2009 - 2021年)。主要结局是根据ROP早期治疗标准发生1型ROP或根据眼科医生的判断进行治疗。展示了DIGIROP-v1.0模型的敏感性、特异性、曲线下面积(AUC)及相应的95%置信区间(CI)和校准图。
DIGIROP-Birth-v1.0模型正确识别出35/43例接受治疗的婴儿(敏感性81.4% [95% CI,66.6% - 91.6%],特异性61.5% [95% CI,57.4% - 65.4%],AUC 0.82 [95% CI,0.75 - 0.90])。在出生后第6 - 14周,DIGIROP-Screen-v1.0模型的敏感性范围为82.6%至100%。该模型遗漏了11例接受治疗的婴儿,这些婴儿均患有严重合并症,即先天性畸形、综合征、脑积水或肠道手术史,但根据DIGIROP-v1.0模型的建议以及本单位的常规标准符合筛查标准。
与瑞典开发组相比,DIGIROP-v1.0模型在这个希腊队列中导致较低的敏感性和较高的特异性。尽管胎龄和出生体重较高,但我们队列中的婴儿接受治疗的ROP发生率高于瑞典,导致对其需要治疗的ROP风险估计不足。建议进一步验证DIGIROP-v2.0模型并进行潜在调整,以最大限度地提高在不同特征人群中的通用性。